Abstract 227P
Background
Even though patients with non-muscle invasive urothelial carcinoma (NMIUC) show favorable survival rates, more than a half of them relapse during follow-up, while up to 20% progress to muscle-invasive urothelial carcinoma (MIUC). As the presence of invasion confers significant prognostic and therapeutic implications for these patients, its accurate detection is imperative; this has prompted the search for biomarkers predictive of invasion, using mostly genomic analysis. In contrast to the extensive genome-based research published so far in the field of BUC, studies utilizing in-depth proteomic analysis on patient-derived tissue samples, directed toward the identification of biomarkers predictive of tumor invasion, have barely been performed.
Methods
A total of 265 radical cystectomy specimens were selected from the Department of Pathology, Seoul National University Hospital (SNUH). This cohort consisted of 39 formalin-fixed paraffin embedded (FFPE) whole tissue samples used for the in-depth proteomics analysis, besides 226 BUC cases processed and analyzed as tissue microarrays (TMAs) to validate the in-depth proteomics findings along with in vitro testsFor proteomic analysis, 31 tissue specimens, consisting of 9 IUP, 12 PUC, and 10 normal urothelium (NU), were included. Machine learning-based feature selection for candidate markers For validation of IUP, we performed immunohistochemical staining in an independent valid. ation cohort composed of 25 IUP and 16 PUC with inverted growth.
Results
Validation of TUBB6 and TGFBI as potential predictive markers of muscle-invasive urothelial carcinoma (MIUC) and prognosis determinants. tubulin beta 6 class V (TUBB6) and TGFBI mRNA high expression and TUBB6 and TGFBI protein expression levels among NMIUC (pTa/pT1) and MIUC (pT2-pT4) (SNUH). From the overall proteomic landscape, The immunohistochemical validation PYGB as a specific biomarker to distinguish between IUP and PUC with inverted growth.
Conclusions
We propose TUBB6 as a novel IHC biomarker to predict invasion and poor prognosis, also select the optimal treatment in BUC patients. We suggest PYGB as a promising immunohistochemical marker for IUP diagnosis in routine practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract